13.3  0.67 (5.3%)		09-13 16:00
Open: 12.72 High: 13.31 Volume: 1,202,068		Pre. Close: 12.63 Low: 12.7 Market Cap: 1,289(M)

Short term
Mid term
Targets	6-month :	19.27	1-year :	22.5
Resists	First :	16.5	Second :	19.27
Pivot price	12.52
Supports	First :	12.27	Second :	9.67
MAs	MA(5) :	12.23	MA(20) :	12.83
	MA(100) :	10.18	MA(250) :	7.75
MACD	MACD :	0.1	Signal :	0.2
%K %D	K(14,3) :	49.6	D(3) :	31.2
RSI	RSI(14): 59.2
52-week	High :	16.5	Low :	2.54

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SPRY ] has closed below upper band by 26.2%. Bollinger Bands are 25.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	13.33 - 13.38	13.38 - 13.43
Low:	12.57 - 12.63	12.63 - 12.69
Close:	13.2 - 13.29	13.29 - 13.39

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Sat, 14 Sep 2024
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $22.75 Consensus PT from Brokerages - MarketBeat

Fri, 13 Sep 2024
We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow - Simply Wall St

Wed, 11 Sep 2024
ARS Pharmaceuticals (SPRY): A Bull Case Theory - Yahoo Finance

Tue, 10 Sep 2024
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewswire

Tue, 10 Sep 2024
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference - StockTitan

Tue, 10 Sep 2024
ARS Pharma seeks FDA nod for needle-free epinephrine - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	-26 (M)
Shares Float	0 (M)
Held by Insiders	9.694e+007 (%)
Held by Institutions	4.455e+007 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.47
Profit Margin	0 %
Operating Margin	-3 %
Return on Assets (ttm)	68 %
Return on Equity (ttm)	-14.8 %
Qtrly Rev. Growth	500000 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-5.667e+007 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-28.3
Price to Sales	0
Price to Cash Flow	0

Dividend	1.207e+007
Forward Dividend	8.74e+006
Dividend Yield	90751900%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.